Yaoyanshe is a CRO technology platform that focuses on providing innovative clinical research services for the medical industry. With a patient-centric approach, Yaoyanshe is committed to becoming the warmest and most reliable technological platform in the pharmaceutical R&D ecosystem.
Leveraging the core advantages of talent, data, and technology, Yaoyanshe offers one-stop services including CRO, SMO, site start-up (SSU), patient recruitment (PRO), FSP (Functional Service Provider), and intelligent data services to all parties involved in drug development. These services effectively reduce R&D costs and shorten development cycles.
The company was founded in 2015 and has received multiple rounds of financing from top-tier investors such as Vision Plus Capital, Matrix Partners China, Genesis Capital, Sequoia Capital, Eastern bell Capital, and GGV Capital.
药研社是专注为医疗行业提供创新型医药研发服务的CRO科技平台，以患者为中心，致力于成为医药研发生态最有温度、最可信赖的科技平台。利用人才、数据、技术的核心优势，药研社为药物研发各方提供包括CRO、SMO、中心快速启动(SSU)、患者招募(PRO)、人力外派(FSP)、智能数据服务等一站式服务，能有效降低研发成本，缩短研发周期。公司于2015年成立，获得元璟资本、经纬中国、元生资本、红杉资本、钟鼎资本、纪源资本等一线投资方多轮融资。
网站
https://www.yaoyanshe.com
药研社 Yaoyanshe的外部链接
所属行业
生物技术研究
规模
501-1,000 人
总部
上海，上海
类型
私人持股
创立
2015
领域
互联网、临床研究、创新药研发、CRO、SMO、SSU和患者招募